Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ART26.12

Next Previous
Drug Profile

ART26.12

Alternative Names: ART 2612; ART-26.12

Latest Information Update: 31 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stony Brook University; The Research Foundation of State University of New York
  • Developer Artelo Biosciences; Stony Brook University
  • Class Antineoplastics; Antipsoriatics; Anxiolytics; Non-opioid analgesics; Skin disorder therapies; Small molecules
  • Mechanism of Action FABP5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Peripheral neuropathies
  • Preclinical Anxiety disorders; Cancer; Pain; Psoriasis

Most Recent Events

  • 12 Mar 2026 Artelo Biosciences has patent protection for ART26.12
  • 01 Mar 2026 ART26 12 is still in preclinical phase trials for Anxiety disorders in the USA (Artelo Bioscience pipeline, March 2026)
  • 24 Feb 2026 Artelo Biosciences plans a phase I multiple ascending dose safety trial in Chemotherapy-induced peripheral neuropathy (In volunteers) in the third quarter of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top